PCM
ALLO icon

Prelude Capital Management’s Allogene Therapeutics ALLO Stock Holding History

Prelude Capital Management’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-33,707
Closed -$364K – 1312
2022
Q3 		$364K Buy
+33,707
New +$458K 0.01% 783

Other funds holding ALLO

TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Prelude Capital Management's ALLO Position: Q4 2022 in Review

Prelude Capital Management sold out of Allogene Therapeutics (ALLO) in Q4 2022, closing a stake of 33,707 shares — an estimated $364K sold.

Prelude Capital Management first reported a position in ALLO in Q3 2022 and held it in 1 quarter. The position peaked at $364K in Q3 2022. 168 funds tracked by Wall St. Rank hold ALLO as of Q4 2022.

  • Prelude Capital Management reported no remaining Allogene Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Prelude Capital Management sold 33,707 Allogene Therapeutics shares in Q4 2022, an estimated $364K.
  • Prelude Capital Management first reported a position in Allogene Therapeutics in Q3 2022 and held it in 1 quarter.
  • Prelude Capital Management's Allogene Therapeutics position peaked at $364K in Q3 2022.
  • 168 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q4 2022.

Based on Prelude Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.